Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
JAK2 mutation + CRLF2 rearrangement
i
Other names:
JTK10, THCYT3, JAK2, Janus Kinase 2, Tyrosine-Protein Kinase JAK2, JAK-2, CRLF2, Cytokine Receptor Like Factor 2, Thymic Stromal Lymphopoietin Protein Receptor, Cytokine Receptor-Like Factor 2, TSLP Receptor, IL-XR, TSLPR, CRL2, Thymic Stromal-Derived Lymphopoietin Receptor, Cytokine Receptor CRL2 Precusor, Cytokine Receptor-Like 2, CRLF2Y, ILXR
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
3717
;
64109
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
JAK2 V617F (4)
JAK2 mutation (4)
CRLF2 rearrangement (4)
JAK2 F547 (2)
JAK2 F694L (1)
JAK2 R683G (1)
JAK2 R938Q (1)
JAK2 rearrangement (1)
CRLF2 mutation (1)
JAK2 I682F (0)
JAK2 QGinsR683 (0)
JAK2 rearrangement (0)
JAK2 R867Q (0)
JAK2 V617F (4)
JAK2 mutation (4)
CRLF2 rearrangement (4)
JAK2 F547 (2)
JAK2 F694L (1)
JAK2 R683G (1)
JAK2 R938Q (1)
JAK2 rearrangement (1)
CRLF2 mutation (1)
JAK2 I682F (0)
JAK2 QGinsR683 (0)
JAK2 rearrangement (0)
JAK2 R867Q (0)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
JAK2 mutation + CRLF2 rearrangement
Acute Myelogenous Leukemia
JAK2 mutation + CRLF2 rearrangement
Acute Myelogenous Leukemia
ruxolitinib
Sensitive: D – Preclinical
ruxolitinib
Sensitive
:
D
ruxolitinib
Sensitive: D – Preclinical
ruxolitinib
Sensitive
:
D
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.